When a Foreign Manufacturer May Not Need Its Own U.S. Entity

A foreign medical-device manufacturer does not automatically need to incorporate a U.S. company merely to obtain FDA clearance, register its foreign establishment, appoint a U.S. Agent, or sell products into the country. FDA contemplates foreign establishments and requires them to identify a U.S. Agent; that agent is a communications contact, not the manufacturer’s American subsidiary. The real question is whether necessary U.S. functions can be allocated externally without leaving contractual, regulatory, or tax gaps.

The distribution model is the starting point. If an independent U.S. distributor purchases, imports, and resells the devices in its own name, the manufacturer may have limited direct U.S. operations. A hybrid-distribution provider may instead perform defined local functions while the manufacturer retains greater commercial control. The analysis changes when the manufacturer owns domestic inventory, invoices customers directly, sets sales terms, or remains responsible for returns, warranties, complaints, and recalls.

“U.S. Agent” can be misleading. The FDA U.S. Agent has a narrow regulatory-communications role and is not automatically a sales representative, importer, distributor, or contracting party. A commercial agent may generate leads or support negotiations, but its authority matters. Personnel who conclude contracts, maintain a fixed business location, hold inventory, or operate as employees can create corporate-registration and tax questions that a limited independent agency arrangement may not.

Import responsibilities also do not necessarily require the manufacturer’s own entity. A foreign company may be able to act as a nonresident Importer of Record after completing the required customs arrangements, or another party may assume that role. Separately, the FDA initial importer must have a staffed physical address in the United States. These functions can be outsourced only where the selected party accepts the associated customs, FDA, recordkeeping, complaint, and reporting responsibilities.

Commercial expectations may produce a different result from the minimum legal position. Customers, insurers, and lenders may require a domestic counterparty, U.S. banking details, locally issued insurance, familiar tax documentation, warranty support, or enforceable service commitments. Contracts must also allocate title, delivery risk, liability, indemnities, returns, field actions, and payment obligations clearly.

Operating without a U.S. entity does not mean operating outside the U.S. tax or registration system. Direct sales, U.S.-based services, personnel, inventory, or an agent’s activities may create a U.S. trade or business, effectively connected income, a treaty permanent establishment, state tax nexus, payroll obligations, or foreign-qualification requirements. Legal and tax advisers must assess the actual operating facts rather than the absence of a subsidiary.

MDD Options’ Hybrid Distribution model can provide the U.S. commercial and compliance infrastructure that might otherwise require a staffed local operation, including import coordination, initial-importer support, inventory, invoicing, fulfillment, returns, complaint routing, and relevant state registrations. This can allow a foreign manufacturer to enter or expand in the United States without immediately establishing its own entity. MDD Options can also map the proposed roles and transactions so legal and tax advisers can assess any remaining entity requirements efficiently.